
This nationwide cohort study assessed the risk of bleeding and mortality associated with non-vitamin K antagonist oral anticoagulants (NOACs) in patients treated with alteplase for acute ischemic stroke. Patients receiving NOACs within 2 days prior to stroke did not exhibit significantly higher risks of intracranial hemorrhage, major bleeding, or in-hospital mortality compared to those without anticoagulant treatment. Propensity score matching and meta-analysis supported these findings, revealing no significant differences between NOACs and warfarin. The study suggests that NOACs before stroke in patients receiving alteplase for acute ischemic stroke are not linked to increased bleeding or mortality risks.
Like
Save
Share